Susceptibility to quinupristin-dalfopristin and linezolid in 839 clinical isolates of gram-positive cocci from Norway

References

• Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis 2003; 36: 1433–7.
   PubMed Web of Science ®Google Scholar
• NORM/NORM-VET 2000. Consumption of antimicrobial agents and occurrence of antimicrobial resistance in Norway. Tromsø/Oslo 2002. ISSN:1502–2307.
   Google Scholar
• Eliopoulos GM. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin Infect Dis 2003; 36: 473–81.
   PubMed Web of Science ®Google Scholar
• Beyer D, Pepper K. The streptogramin antibiotics: updates on their mechanisms of action. Expert Opin Investig Drugs 1998; 7: 591–9.
   PubMedGoogle Scholar
• Lina G, Quaglia A, Reverdy ME, Leclercq R, Vandenesch F, Etienne J. Distribution of genes encoding resistance to macrolides, lincosamides, and streptogramins among staphylococci. Antimicrob Agents Chemother 1999; 43: 1062–6.
   PubMed Web of Science ®Google Scholar
• Malbruny B, Canu A, Bozdogan B, Fantin B, Zarrouk V, Dutka-Malen S, et al. Resistance to quinupristin-dalfopristin due to mutation of L22 ribosomal protein in Staphylococcus aureus. Antimicrob Agents Chemother 2002; 46: 2200–7.
   PubMed Web of Science ®Google Scholar
• Kehoe LE, Snidwongse J, Courvalin P, Rafferty JB, Murray IA. Structural basis of synercid (quinupristin-dalfopristin) resistance in Gram-positive bacterial pathogens. J Biol Chem 2003; 278: 29963–70.
   Google Scholar
• Leclercq R, Nantas L, Soussy CJ, Duval J. Activity of RP 59500, a new parenteral semisynthetic streptogramin, against staphylococci with various mechanisms of resistance to macrolidelincosamide-streptogramin antibiotics. J Antimicrob Chemother 1992; 30 (Suppl A): 67–75.
   Google Scholar
• Werner G, Klare I, Witte W Molecular analysis of streptogramin resistance in enterococci. Int J Med Microbiol 2002; 292: 81–94.
   PubMed Web of Science ®Google Scholar
• Singh KV, Weinstock GM, Murray BE. An Enterococcus faecalis ABC homologue (Lsa) is required for the resistance of this species to clindamycin and quinupristin-dalfopristin. Antimicrob Agents Chemother 2002; 46: 1845–50.
   Google Scholar
• Zurenko GE, Yagi BH, Schaadt RD, Allison JW, Kilburn JO, Glickman SE, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996; 40: 839–45.
   PubMed Web of Science ®Google Scholar
• Shinabarger DL, Marotti KR, Murray RW, Lin AH, Melchior EP, Swaney SM, et al. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother 1997; 41: 2132–6.
   PubMed Web of Science ®Google Scholar
• Prystowsky J, Siddiqui F, Chosay J, Shinabarger DL, Millichap J, Peterson LR, Noskin GA. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob Agents Chemother 2001; 45: 2154–6.
   Google Scholar
• Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358: 207–8.
   PubMed Web of Science ®Google Scholar
• Simonsen GS, Småbrekke L, Monnet DL, Sørensen TL, Møller JK, Kristinsson KG, et al. Prevalence of resistance to ampicillin, gentamicin and vancomycin in Enterococcus faecalis and Enterococcus faecium isolates from clinical specimens and use of antimicrobials in 5 Nordic hospitals. J Antimicrob Chemother 2003; 51: 323–31.
   PubMed Web of Science ®Google Scholar
• Andersen BM, Dalen HE, Steinbakk M, Syversen G, Bruun JN, Magnæs B, et al. [Methicillin resistant yellow staphylococci]. Tidsskr Nor Laegeforen 1998; 118: 1182–5. (In Norwegian).
   PubMedGoogle Scholar
• Brakstad OG, Mæland JA, Tveten Y. Multiplex polymerase chain reaction for detection of genes for Staphylococcus aureus thermonuclease and methicillin resistance and correlation with oxacillin resistance. APMIS 1993; 101: 681–8.
   PubMed Web of Science ®Google Scholar
• E-test application sheet-EAS008, AB Biodisk, Solna, Sweden.
   Google Scholar
• Pedersen MK, Høiby EA, Frøholm LO, Hasseltvedt V, Lermark G, Caugant DA. Systemic pneumococcal disease in Norway 1995–2001: capsular serotypes and antimicrobial resistance. Epidemiol Infect (in press.)
   Google Scholar
• Vilhelmsson SE, Tomasz A, Kristinsson KG. Molecular evolution in a multidrug-resistant lineage of Streptococcus pneumoniae: emergence of strains belonging to the serotype 6B Icelandic clone that lost antibiotic resistance traits. J Clin Microbiol 2000; 38: 1375–81.
   Google Scholar
• Henwood CJ, Livermore DM, Johnson AP, James D, Warner M, Gardiner A. Susceptibility of Gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group. J Antimicrob Chemother 2000; 46: 931–40.
   PubMed Web of Science ®Google Scholar
• Ballow CH, Jones RN, Biedenbach DJ. A multicentre evaluation of linezolid antimicrobial activity in North America. Diagn Microbiol Infect Dis 2002; 43: 75–83.
   PubMed Web of Science ®Google Scholar
• Bolmstrom A, Ballow CH, Qwarnstrom A, Biedenbach DJ, Jones RN. Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: report from The Zyvox Antimicrobial Potency Study (ZAPS-Europe). Clin Microbiol Infect 2002; 8: 791–800.
   Google Scholar
• Mutnick AH, Biedenbach DJ, Turnidge JD, Jones RN. Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998–2000. Diagn Microbiol Infect Dis 2002; 43: 65–73.
   PubMed Web of Science ®Google Scholar